nifekalant

{{Short description|Chemical compound}}

{{Drugbox

| verifiedrevid = 444386935

| IUPAC_name = 6-[(2-{(2-hydroxyethyl)[3-(4-nitrophenyl)propyl]amino}ethyl)amino]-1,3-dimethylpyrimidine-2,4(1H,3H)-dione

| image = Nifekalant.png

| tradename =

| Drugs.com = {{drugs.com|international|nifekalant}}

| pregnancy_AU =

| pregnancy_US =

| pregnancy_category =

| legal_AU =

| legal_CA =

| legal_UK =

| legal_US =

| legal_status = Rx-only

| routes_of_administration = IV

| bioavailability =

| protein_bound =

| metabolism =

| elimination_half-life =

| excretion =

| CAS_number_Ref = {{cascite|correct|??}}

| CAS_number = 130636-43-0

| ATC_prefix = none

| ATC_suffix =

| ATC_supplemental =

| PubChem = 4486

| DrugBank_Ref = {{drugbankcite|correct|drugbank}}

| DrugBank =

| UNII_Ref = {{fdacite|correct|FDA}}

| UNII = 5VZ7GZM43E

| ChemSpiderID = 4331

| chemical_formula =

| C=19 | H=27 | N=5 | O=5

| smiles = Cn1c(NCCN(CCO)CCCc2ccc([N+](=O)[O-])cc2)cc(=O)n(C)c1=O

| StdInChI = 1S/C19H27N5O5/c1-21-17(14-18(26)22(2)19(21)27)20-9-11-23(12-13-25)10-3-4-15-5-7-16(8-6-15)24(28)29/h5-8,14,20,25H,3-4,9-13H2,1-2H3

| StdInChIKey = OEBPANQZQGQPHF-UHFFFAOYSA-N

}}

Nifekalant (INN) is a class III antiarrhythmic agent approved in Japan for the treatment of arrhythmias and ventricular tachycardia.{{cite journal |vauthors=Oyabe A, Sano H |title=Pharmacological and clinical profile of nifekalant (shinbit injection), a class III antiarrhythmic drug |journal=Nippon Yakurigaku Zasshi |volume=119 |issue=2 |pages=103–9 |date=February 2002 |pmid=11862758 |doi= 10.1254/fpj.119.103|url=https://www.jstage.jst.go.jp/article/fpj/119/2/119_2_103/_article|doi-access=free }} It has the brand name Shinbit.